Compare AstraZeneca plc (AZN) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

HPE trades at $47.24, down 2.61% on the day, with a bullish technical signal from moving averages. Recent earnings beats and a consensus price target of $69.69 suggest upside potential. The company reported revenue of $34.30B in 2025, though net income fell sharply to $57M. Strong AI infrastructure demand and a nearly $6B backlog, as noted by The Motley Fool on July 9, 2026, highlight growth catalysts.

Outlook is positive with AI-driven demand boosting revenue projections to $38.8B in 2026. Risks include high debt-to-asset ratio of 29.48% in 2025 and margin pressures. Analysts are mixed with 46% buy ratings, indicating cautious optimism for long-term investors amid near-term volatility.